290 related articles for article (PubMed ID: 22427632)
1. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
[TBL] [Abstract][Full Text] [Related]
2. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
4. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
[TBL] [Abstract][Full Text] [Related]
5. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
6. The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.
Fonteneau JF; Brilot F; Münz C; Gannagé M
J Immunol; 2016 Jan; 196(1):64-71. PubMed ID: 26608910
[TBL] [Abstract][Full Text] [Related]
7. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
[TBL] [Abstract][Full Text] [Related]
8. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
9. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
11. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
12. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
13. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
[TBL] [Abstract][Full Text] [Related]
14. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
[TBL] [Abstract][Full Text] [Related]
15. Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells.
Susumu S; Nagata Y; Ito S; Matsuo M; Valmori D; Yui K; Udono H; Kanematsu T
Cancer Sci; 2008 Jan; 99(1):107-12. PubMed ID: 17991294
[TBL] [Abstract][Full Text] [Related]
16. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
[TBL] [Abstract][Full Text] [Related]
17. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
19. Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.
Zandvliet ML; Kester MG; van Liempt E; de Ru AH; van Veelen PA; Griffioen M; Guchelaar HJ; Falkenburg JH; Meij P
J Immunother; 2012; 35(2):142-53. PubMed ID: 22306902
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
